Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00101920 | ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) | PHASE2 | COMPLETED | 50 | — | — | Jun 1, 2003 | Dec 1, 2004 | Oct 15, 2010 | - | — |
| NCT00034346 | ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) | PHASE2 | COMPLETED | 194 | — | — | Jan 1, 2002 | - | Dec 24, 2007 | - | — |
| Arm | Type | Description |
|---|---|---|
| ABX-EGF | EXPERIMENTAL | Open-label, single arm panitumamab monotherapy |
| Name | Type | Description |
|---|---|---|
| ABX-EGF | DRUG | 2.5 mg/kg by an infusion pump over one hour |
| paclitaxel | DRUG | - |
| carboplatin | DRUG | - |
Inclusion Criteria: * 18 years of age or older. * Diagnosis of NSCLC. * Unidimensionally measurable disease. * Documented disease progression within 6 months of the subject's last dose of carboplatin and paclitaxel in treatment arm 1, part 2 of Immunex Protocol 054.0004 (Amgen Protocol 20025404). *...